Physician profile
Ali Akbar
NPI 1740411370
$4,521.52
in general payments reported to CMS, 2019-2025
30 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $157 · 2021: $234 · 2022: $1,353 · 2023: $878 · 2024: $654 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.99 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,256.92 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.29 | 2019-2024 | Xifaxan, Plenvu, Uceris |
| Ferring Pharmaceuticals INC. | $269.42 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $176.23 | 2019-2022 | |
| Pfizer INC. | $170.22 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $121.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.12 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $101.39 | 2019-2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $101.27 | 2022-2023 | |
| Ardelyx, INC. | $95.05 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $94.84 | 2019-2024 | |
| Celgene Corporation | $72.34 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $71.00 | 2019-2023 | Dificid |
| Boston Scientific Corporation | $65.02 | 2019-2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $62.30 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $61.81 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $36.84 | 2024-2025 | Zenpep |
| Genzyme Corporation | $26.34 | 2023 | |
| Novo Nordisk INC | $23.76 | 2024 | |
| Daiichi Sankyo INC. | $23.31 | 2019 | |
| Redhill Biopharma INC. | $20.81 | 2022 | |
| Braintree Laboratories, INC. | $17.85 | 2024 | Suflave |
| Celltrion USA INC. | $16.15 | 2024 | Vegzelma |
| Enterra Medical, INC. | $15.95 | 2023 | |
| Aurinia Pharma U.S., INC. | $15.81 | 2025 | Lupkynis |
| Ambu INC. | $15.18 | 2022 | |
| Olympus America INC. | $14.53 | 2020 | |
| Medtronic, INC. | $14.44 | 2022 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Ucb, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.